Close Menu

More articles about Research Funding

The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.

The firms supporting the new lab include Thermo Fisher Scientific, Canon Medical, and Siemens Healthineers, all of which will contribute their know-how and technologies to the effort.

The new funding opportunities come as part of the NIH's Rapid Acceleration of Diagnostics program, which aims to support SARS-CoV-2 testing technologies. 

The test will comprise a smartphone-powered single-use, disposable device that detects active SARS-CoV-2 infection based on the presence of viral proteins.

The lawmakers requested the secretary to direct money from the Public Health and Social Services Emergency Fund to support clinical labs.

The winners will each get a sample set from AACC's Universal Sample Bank, which has blood samples from healthy individuals collected to help medical studies.

The research group said its test has the potential to boost limits of detection one hundredfold over ELISA platforms in testing for antibodies against SARS-CoV-2.

The award amount is about $2.3 million, BARDA said, while a Beckman Coulter spokesperson added the full contract is valued at up to $8.06 million.

The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.

The IMI announced the call in February with an initial budget of €45 million but raised the total funding amount to €72 million.

The effort is receiving $1.5 billion in funding with up to $500 million set aside for a competition among researchers developing rapid testing technologies.

The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.

Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.

The multiplex assay is designed to detect both the SARS-CoV-2 nucleocapsid protein from nasal swabs and patient-derived antibodies against the viral spike protein 1 from blood drops.

In October the company received $15 million in funding from BARDA and venture capital firms to advance its early sepsis detection technology.

The total relief package totals $484 billion, including $11 billion for states, localities, territories, tribes, and employers to scale up SARS-CoV-2 testing.

The test is expected to run on Tangen's GeneSpark nucleic acid amplification platform and achieve a CLIA waiver for use in doctors' offices.

Some of the supplemental will go toward the purchase of lab equipment, supplies, staffing, shipping, and other resources, HHS said.

MBio is developing the system for use with human host-response biomarker assays that can be used to identify gravely ill or highly contagious individuals.

The Swedish firms plans to launch clinical performance studies in support of getting CE marking for its QuickMIC system.